CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo

• Published in: Journal of Immunology 2006-09, Vol.177 (5), p.3063-3073
• Main Authors: Haas, Karen M, Sen, Suman, Sanford, Isaac G, Miller, Ann S, Poe, Jonathan C, Tedder, Thomas F
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - immunology; B-Lymphocytes - cytology; B-Lymphocytes - immunology; B-Lymphocytes - metabolism; Calcium - metabolism; Cell Survival; Cells, Cultured; Leukemia, B-Cell - immunology; Leukemia, B-Cell - metabolism; Leukemia, B-Cell - pathology; Ligands; Mice; Phenotype; Receptors, Fc - immunology; Sialic Acid Binding Ig-like Lectin 2 - genetics; Sialic Acid Binding Ig-like Lectin 2 - immunology; Sialic Acid Binding Ig-like Lectin 2 - metabolism
• ISSN: 0022-1767; 1550-6606; 1365-2567
• DOI: 10.4049/jimmunol.177.5.3063

The CD22 extracellular domain regulates B lymphocyte function by interacting with alpha2,6-linked sialic acid-bearing ligands. To understand how CD22 ligand interactions affect B cell function in vivo, mouse anti-mouse CD22 mAbs were generated that inhibit CD22 ligand binding to varying degrees. Remarkably, mAbs which blocked CD22 ligand binding accelerated mature B cell turnover by 2- to 4-fold in blood, spleen, and lymph nodes. CD22 ligand-blocking mAbs also inhibited the survival of adoptively transferred normal (73-88%) and malignant (90%) B cells in vivo. Moreover, mAbs that bound CD22 ligand binding domains induced significant CD22 internalization, depleted marginal zone B cells (82-99%), and reduced mature recirculating B cell numbers by 75-85%. The CD22 mAb effects were independent of complement and FcRs, and the CD22 mAbs had minimal effects in CD22AA mice that express mutated CD22 that is not capable of ligand binding. These data demonstrate that inhibition of CD22 ligand binding can disrupt normal and malignant B cell survival in vivo and suggest a novel mechanism of action for therapeutics targeting CD22 ligand binding domains.